2016 GRC NPC Dennis Lo (Chinese University of Hong Kong, Hong Kong SAR China) “Plasma DNA Analysis for Detecting NPC: Biological Insights and Clinical Applications” 盧煜明 (Wiki https://goo.gl/HTNGFn) 香港中文大學網站 https://goo.gl/03EPTe http://goo.gl/i7PNRf ) Size based molecular diagnosis (difference between maternal and fetal , because the fetal DNA has no linker, therefore is 10 bp shorter) […]
GRC NPC – Lo, Yuk-Ming Dennis Read More »
Elaine Fuchs (The Rockefeller University, USA HHMI Investigator) “Transition of Normal Epithelia to Cancer”Webpage http://www.rockefeller.edu/research/faculty/labheads/ElaineFuchs/#content a student of Howard Green, who just passed away several mo ago The foundation of embryonic stem cell culture to come in 1980s burn therapy quiescent stem cell and primed stem cells awaiting for activation Hair follicle stem cells BMP signaling
GRC NPC – Fuchs, Elaine Read More »
Hans Clevers (Hubrecht Institute, The Netherlands)“Wnt Signaling and Cancer” The champion of all stem cells : crypt base paneth cells Wnt is required to maintain crypt stem cells in colon cancer，Wnt is locked in On state。 Lqr5 is an unusual component that marks stem cells in the crypts。 15 stem cell to begin (mixed with1
GRC NPC – Clevers, H Read More »
2018 GRC NPC [NPC tumorigenesis model] WES-seq of 111 NPC patient Nat Commun 18: 14121, 2017 LCM enrichment of tumor cells. -> higher somatic mutation than the Singapore study (because of LCM?) LMP1 activates both canonical and non-canonical NFKB pathways Homozygous deletion f BIRC2(cIAP) and BIRC3(cIAP2) in primary NPC Identification of a novel 12p13.3 amplicon
Fei-Fei Liu (Princess Margaret Hospital, Canada)“Prognostic Significance of miRNA Signatures for Detection of Metastatic NPC” metastatic NPC, metastamirs let-7 miR9 Nanostring 654 miRNA + 34 EBV mi RNA + mi RNA from other viruses on 124 patients Bruce Oncotarget , 2015 miRNAS 154 + miRNA 449 – MENA 140 – MIRNA 34c (Bruce
GRC NPC – Liu, Fei-Fei Read More »
Xin Lu (Ludwig Institute for Cancer Research, United Kingdom) “p53, a Key Regulator of Genomic Stability in Cancer” Discovery of p53: 1979 about the same time “tumor antigen” by Lloyd and Old, PNAS. Binding partner of large T antigen of SV40 (A Larid and David Lane) p53 mutation in 30–40% BL, why only 9 % in
Andrew Futreal (University of Texas MD Anderson Cancer Center, USA) “Cancer Genomics and Evolution” tumors heterogeneous from one patient to another intratumor heterogeneity—a state where subclonal subpopulations within the same tumor accumulate different kinds of mutations over time (65% heterogeneity in RCC) 1 mutation/wk, 40 mutations / year APOLLO platform https://goo.gl/uRmjHX Moon shot platform 40% subclonal
GRC NPC – Futreal, Andrew Read More »
Allan Hildesheim (National Cancer Institute, NIH, USA) “Use of Viral and Genetic Markers for Risk Stratification for Development of Screening Programs for the Early Detection of NPC” 1987 Use of viral and genetic markers for NPC risk stratification. 16% cancers are caused by infectious agents (Lancet Oncol 2012, de Martel) EBV vaccination: EBV gp350 (Coghill et
GRC NPC – Hildesheim, Allan Read More »
Harald zur Hausen (German Cancer Research Center, Germany) “Discovery and Early Studies of EBV in Burkitt’s Lymphoma and NPC” EBV provides a step in the malignization of pre-malignant NPC lesion (methylation of p16) Endemic multiple sclerosis TGFb is an inducing agent for EBV lytic replication Vit D deficiency -> TGFb increase -> EBV reactivation EBV enhances
GRC NPC – zur Hausen Read More »
Wed Poster #5 Dr. Timothy Wai Ho Shuen 孫傳豪 Singapore TESSA therapeutics (http://goo.gl/zdbYpA) NPC stage IVb patients → 抽300-400 ml blood → 一部分加B95-8 養成LCL → 養成的LCL與病人自己PBL aliquot co-culture → mapping 出effective CTL → expand → 打回去病人身上 (response rate還蠻不錯的! 整個時程約1-2個月) Wed Poster #9 University of Malaya Velapasamy, Sharmila … LF Yap SB-431542 10 uM, a TGFBRI
GRC NPC – Unclassified Read More »